Zai Lab's Losses Widen as Licensing Costs Offset Revenue Rebound
Zai Lab posted a $50.8 million net loss in the second quarter as higher licensing fees outpaced a sequential revenue recovery to $106.3 million.
Zai Lab (ZLAB) reported second-quarter revenue of $106.3 million, down 3% from $110.0 million a year earlier, as a widening net loss underscored the cost of a licensing-heavy pipeline strategy even as the drugmaker's core products showed signs of stabilizing.
The results mark a continuation of a reversal that began earlier this year. Zai Lab's revenue grew at double-digit rates through 2025 — up 9% in the second quarter, 14% in the third and 17% in the fourth — before swinging to declines of 6% in the first quarter of 2026 and 3% in the second. Product revenue net told the same story, falling 3% year-over-year to $105.8 million from $109.1 million.
Within the quarter, the company found some footing. Total revenue rose 7% sequentially from $99.6 million in the first quarter, and product revenue net climbed 11% sequentially to $105.8 million from $95.6 million, due to the stabilization of ZEJULA and volume growth in VYVGART. ZEJULA sales had fallen sharply to $30.0 million in the first quarter from $49.5 million a year earlier amid generic olaparib procurement pressure before leveling off in the second quarter. VYVGART followed a similar arc, moving from a pricing-driven decline in the first quarter — sales of $17.6 million versus $18.1 million a year earlier after an NRDL renewal pricing adjustment — to double-digit volume growth in the second quarter.
The stabilization in sales did not translate into a narrower loss. Research and development expenses rose 22% year-over-year to $61.8 million from $50.6 million, driven by higher licensing fees under collaboration agreements that were only partially offset by lower clinical and pre-clinical spending. Selling, general and administrative expenses held roughly flat at $72.9 million versus $71.0 million, reflecting continued organizational streamlining. The combination pushed the operating loss to $76.5 million, or $60.4 million on an adjusted basis, and widened the net loss to $50.8 million, or $0.46 a share, from $40.7 million, or $0.37 a share, a year earlier. The move breaks with the trend Zai Lab reported through 2025, when operating losses improved 28% year-over-year in both the second and third quarters.
Zai Lab's cash position also thinned. Cash, short-term investments and current restricted cash fell to $717.5 million as of June 30 from $761.3 million three months earlier, a drawdown of roughly $43.8 million in the quarter. Cash and cash equivalents alone declined to $607.5 million from $679.6 million at the end of 2025.
The anchor release did not reiterate the profitability timeline Zai Lab emphasized in 2025, when it stated it was "on track to achieve profitability in Q4 2025". Full-year 2025 revenue guidance had already been cut once, from a reaffirmed $560 million to $590 million range in the second quarter to "at least $460 million" by the third quarter, before actual 2025 revenue landed at $460.2 million — the low end of the revised guide and well short of the original range.
Zai Lab pointed to pipeline progress as a counterweight to the financial slippage. KarXT, a schizophrenia treatment the company describes as the first therapy with a novel mechanism of action for the condition in more than 70 years, launched commercially in mainland China in June, with "encouraging early launch trends". TIVDAK received approval from China's National Medical Products Administration the same month for recurrent or metastatic cervical cancer, becoming the first antibody-drug conjugate approved in China for that indication. The company's Zoci program also picked up an FDA Orphan Drug Designation in July and an EMA Orphan Drug Designation in June for neuroendocrine carcinomas, along with a second FDA Fast Track Designation in May for extrapulmonary neuroendocrine carcinomas.